amcure GmbH - Matthias Klaften

Cancer is one of the major causes of death worldwide with an expected 13.3 million deaths in 2020. While modern target-specific drugs and medical technology offer an improved treatment of the primary tumor, the effective treatment of metastases as the main cause of death from cancer is still in its beginning. As one of the very few companies, amcure develops a novel approach with a proven effect on the primary tumor, the tumor spreading (metastasis), as well the remission of already established metastases. By addressing the novel target CD44v6, a co-receptor for several critical cellular pathways for cancer development and metastasis, amcure combines the advantages of a target specific and a broadband drug therapy. If the effect observed in several relevant animal models can be proven in clinical studies, the company has the potential to offer a breakthrough therapy giving new hope for patients with metastasizing carcinomas that cannot yet be treated adequately.